{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-255166","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.584695+00:00","generated_at":"2026-05-30T02:21:15.154022+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bicara Therapeutics Q3 net loss $17.5M; cash $520.8M; pivotal HNSCC trial on track","bullets":["Cash and cash equivalents $520.8M as of Sep 30, 2024, funding operations into H1 2029.","Net loss of $17.5M for Q3 2024 vs $22.8M in Q3 2023 (prior year included $13.3M non-cash charge).","IPO in Sep 2024 raised ~$362M gross from 20.125M shares at $18.00; listed on Nasdaq as BCAX.","Pivotal Phase 2/3 trial FORTIFI-HN01 of ficerafusp alfa in 1L R/M HNSCC expected to start late Q4 2024 or early Q1 2025.","Phase 1/1b data showed 64% ORR, 18% CR, median PFS 9.8 months in frontline HPV-negative R/M HNSCC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-255166","json":"https://secwatch.observer/filing/0001193125-24-255166.json","markdown":"https://secwatch.observer/filing/0001193125-24-255166.md","text":"https://secwatch.observer/filing/0001193125-24-255166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000119312524255166/0001193125-24-255166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000119312524255166/d793839d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:21:15.154022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}